BiotechTube
BlueSky Immunotherapies

BlueSky Immunotherapies

Vienna, Austria· Est.
blueskyvaccines.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

BlueSky Immunotherapies is a Vienna-based biotech leveraging its novel delNS viral vector platform to develop immunotherapies for cancer and infectious diseases. Its technology is designed to induce potent interferon responses, activating multiple immune cell types and creating a hostile environment for tumors and viruses. The company has advanced its lead HPV-targeted programs into Phase 1/2 clinical trials and has demonstrated compelling proof-of-concept in a veterinary oncology setting, validating the platform's broad potential.

OncologyInfectious Diseases

Technology Platform

Proprietary delNS viral vector platform based on interferon-inducing, NS1-deleted influenza A viruses. Engineered to potently stimulate Type I interferon responses, activating innate and adaptive immunity (NK cells, CTLs, dendritic cells) while inhibiting immunosuppressive cells, and to express tumor-associated antigens for targeted immunotherapy.

Funding History

2
Total raised:$15M
Series A$12M
Seed$3M

Opportunities

The large, underserved population with existing HPV infection creates a significant market for therapeutic vaccines targeting precancerous lesions and cancer.
The platform's ability to create an inflamed tumor microenvironment presents a major opportunity for combination therapies with checkpoint inhibitors, particularly in HPV-positive head and neck cancer.
Successful validation in lead programs could enable rapid expansion into other high-value oncology indications like breast and prostate cancer.

Risk Factors

The company faces significant clinical risk, as early-phase efficacy and safety must be confirmed in larger, controlled trials.
The entire pipeline is dependent on the single delNS platform, creating concentrated technology risk.
As a small, pre-revenue private company, BlueSky is vulnerable to financing challenges and will likely require a partnership to commercialize any product, introducing competitive and execution risks.

Competitive Landscape

BlueSky competes in the crowded therapeutic HPV vaccine and oncolytic virus spaces, facing companies like INOVIO, Advaxis (now Ayala Pharmaceuticals), and others developing immunotherapies for HPV-related diseases. Its primary differentiation is the potent, dual-mechanism interferon induction of its delNS platform. In broader immuno-oncology, it competes with numerous companies developing cancer vaccines and combination regimens, where its unique mechanism of immune activation must prove superior in clinical outcomes.

More companies in Immunotherapy / Immuno-Oncology →More companies in Austria →